Forthcoming Phase II Study of Durvalumab (MEDI4736) Plus Chemotherapy for Small Cell Lung Cancer with Brain Metastases

BACKGROUND: The standard of care for extensive-stage small cell lung cancer (ES-SCLC) is an immune checkpoint inhibitor (ICI) combined with platinum-etoposide (PE) chemotherapy. At initial diagnosis, about 25% of ES-SCLC patients have brain metastases, which are associated with a poor prognosis. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Shiraishi, Yoshimasa, Shimose, Takayuki, Tsuchiya-Kawano, Yuko, Ishii, Hidenobu, Daga, Haruko, Ito, Kentaro, Saruwatari, Koichi, Okamoto, Isamu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9760036/
https://www.ncbi.nlm.nih.gov/pubmed/36540201
http://dx.doi.org/10.2147/CMAR.S391220

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9760036/
https://www.ncbi.nlm.nih.gov/pubmed/36540201
http://dx.doi.org/10.2147/CMAR.S391220

Ejemplares similares